CN114369573B - Method for constructing in-situ primary nasopharyngeal carcinoma animal model - Google Patents
Method for constructing in-situ primary nasopharyngeal carcinoma animal model Download PDFInfo
- Publication number
- CN114369573B CN114369573B CN202011107955.9A CN202011107955A CN114369573B CN 114369573 B CN114369573 B CN 114369573B CN 202011107955 A CN202011107955 A CN 202011107955A CN 114369573 B CN114369573 B CN 114369573B
- Authority
- CN
- China
- Prior art keywords
- cells
- organoids
- culture medium
- tumor
- nasopharyngeal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 35
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 title claims abstract description 26
- 206010061306 Nasopharyngeal cancer Diseases 0.000 title claims abstract description 26
- 201000011216 nasopharynx carcinoma Diseases 0.000 title claims abstract description 26
- 238000011065 in-situ storage Methods 0.000 title claims abstract description 14
- 238000010171 animal model Methods 0.000 title claims abstract description 12
- 210000002220 organoid Anatomy 0.000 claims abstract description 46
- 239000001963 growth medium Substances 0.000 claims abstract description 15
- 210000001989 nasopharynx Anatomy 0.000 claims abstract description 7
- 238000010353 genetic engineering Methods 0.000 claims abstract description 6
- 230000005740 tumor formation Effects 0.000 claims abstract description 3
- 108010082117 matrigel Proteins 0.000 claims description 25
- 210000001519 tissue Anatomy 0.000 claims description 19
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 239000006228 supernatant Substances 0.000 claims description 12
- 239000006143 cell culture medium Substances 0.000 claims description 10
- 230000029087 digestion Effects 0.000 claims description 10
- 238000012258 culturing Methods 0.000 claims description 9
- 238000010790 dilution Methods 0.000 claims description 9
- 239000012895 dilution Substances 0.000 claims description 9
- 239000002609 medium Substances 0.000 claims description 8
- 101150041972 CDKN2A gene Proteins 0.000 claims description 7
- 101100239628 Danio rerio myca gene Proteins 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 6
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 5
- 108010019160 Pancreatin Proteins 0.000 claims description 5
- 229960004308 acetylcysteine Drugs 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 229940055695 pancreatin Drugs 0.000 claims description 5
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 claims description 4
- 102100028412 Fibroblast growth factor 10 Human genes 0.000 claims description 4
- 101000917237 Homo sapiens Fibroblast growth factor 10 Proteins 0.000 claims description 4
- 101000825954 Homo sapiens R-spondin-1 Proteins 0.000 claims description 4
- 102100022762 R-spondin-1 Human genes 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 4
- 238000003384 imaging method Methods 0.000 claims description 4
- 102000045246 noggin Human genes 0.000 claims description 4
- 108700007229 noggin Proteins 0.000 claims description 4
- 239000003550 marker Substances 0.000 claims description 3
- 229960003966 nicotinamide Drugs 0.000 claims description 3
- 235000005152 nicotinamide Nutrition 0.000 claims description 3
- 239000011570 nicotinamide Substances 0.000 claims description 3
- 108700020796 Oncogene Proteins 0.000 claims description 2
- 108700020978 Proto-Oncogene Proteins 0.000 claims description 2
- 102000052575 Proto-Oncogene Human genes 0.000 claims description 2
- GKDWRERMBNGKCZ-RNXBIMIWSA-N gastrin-17 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 GKDWRERMBNGKCZ-RNXBIMIWSA-N 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 230000003472 neutralizing effect Effects 0.000 claims description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 1
- 102200006539 rs121913529 Human genes 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 37
- 238000010362 genome editing Methods 0.000 abstract description 11
- 238000011161 development Methods 0.000 abstract description 5
- 238000002360 preparation method Methods 0.000 abstract description 5
- 238000001727 in vivo Methods 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 45
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 16
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 10
- 241000700605 Viruses Species 0.000 description 10
- 101150105104 Kras gene Proteins 0.000 description 9
- 239000003636 conditioned culture medium Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 6
- 108091033409 CRISPR Proteins 0.000 description 5
- 230000002018 overexpression Effects 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 4
- 241000713666 Lentivirus Species 0.000 description 4
- 108060001084 Luciferase Proteins 0.000 description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000011774 genetically engineered animal model Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 239000012583 B-27 Supplement Substances 0.000 description 2
- 238000010354 CRISPR gene editing Methods 0.000 description 2
- 102400000921 Gastrin Human genes 0.000 description 2
- 108010052343 Gastrins Proteins 0.000 description 2
- 206010064571 Gene mutation Diseases 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 239000005700 Putrescine Substances 0.000 description 2
- 108091027544 Subgenomic mRNA Proteins 0.000 description 2
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 238000003208 gene overexpression Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000007813 immunodeficiency Effects 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 235000014666 liquid concentrate Nutrition 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 229960001471 sodium selenite Drugs 0.000 description 2
- 235000015921 sodium selenite Nutrition 0.000 description 2
- 239000011781 sodium selenite Substances 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 101150028074 2 gene Proteins 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 101001011741 Bos taurus Insulin Proteins 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 239000012580 N-2 Supplement Substances 0.000 description 1
- FABQUVYDAXWUQP-UHFFFAOYSA-N N4-(1,3-benzodioxol-5-ylmethyl)-6-(3-methoxyphenyl)pyrimidine-2,4-diamine Chemical compound COC1=CC=CC(C=2N=C(N)N=C(NCC=3C=C4OCOC4=CC=3)C=2)=C1 FABQUVYDAXWUQP-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940107161 cholesterol Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000031083 ear cancer Diseases 0.000 description 1
- 230000005584 early death Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000022924 malignant ear neoplasm Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 108010008217 nidogen Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000004963 pathophysiological condition Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/062—Sensory transducers, e.g. photoreceptors; Sensory neurons, e.g. for hearing, taste, smell, pH, touch, temperature, pain
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/12—Animals modified by administration of exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
- C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/46—Amines, e.g. putrescine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/119—Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/345—Gastrin; Cholecystokinins [CCK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/39—Steroid hormones
- C12N2501/392—Sexual steroids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/405—Cell cycle regulated proteins, e.g. cyclins, cyclin-dependant kinases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/415—Wnt; Frizzeled
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
- C12N2509/10—Mechanical dissociation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Environmental Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Animal Behavior & Ethology (AREA)
- Acoustics & Sound (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a preparation method of an in-situ primary nasopharyngeal carcinoma tumor model, and belongs to the field of tumor animal models. The invention cultures the mouse nasopharyngeal cells into organoids by a specific culture medium, then carries out gene editing on the organoids, and injects the organoids back into the mouse nasopharynx to enable the organoids to develop into tumors. Compared with a genetic engineering tumor animal model, the method provided by the invention has the advantages of short time consumption and high tumor formation rate; compared with an animal model of transplanted tumor, the method has the in-vivo microenvironment for tumor generation and development, and is more similar to the truest state of nasopharyngeal carcinoma.
Description
Technical Field
The invention belongs to the field of tumor animal models.
Background
Nasopharyngeal carcinoma refers to a malignancy that occurs in the top and side walls of the nasopharyngeal cavity. The epidemic disease area is mainly in east Asia and southeast Asia, is one of the high malignant tumors in China, and the incidence rate is the first malignant tumor of ear, nose and throat.
In the process of researching the occurrence and development mechanism of nasopharyngeal carcinoma and developing the nasopharyngeal carcinoma therapeutic drug, the nasopharyngeal carcinoma animal model is not separated.
The nasopharyngeal carcinoma animal models currently used in scientific research are mainly classified into three types, including genetically engineered animal models, tumor cell line transplantation tumor models, and human xenograft tumor models (PDX, patient derived Xenograft model).
The genetically engineered animal model has good tumor microenvironment and good repeatability, and the immune system is free of defects, but the genetically engineered animal model needs to be used for preparing transgenic animals, and has high cost and long preparation period. The tumor cell line transplantation tumor model only needs to implant a human tumor cell line into a model animal, is easy to prepare and high in repeatability, but an immunodeficiency mouse is needed, and the obtained tumor is not in-situ primary tumor and is greatly different from the actual development condition and pathophysiological condition of the tumor. The PDX model is prepared by inoculating tumor tissue in a patient into a model animal body, is easy to prepare, has genotype close to that of an actual tumor, but is not in-situ tumor, and cannot provide in-situ microenvironment of nasopharyngeal tissue, so that related biological characteristics of human tumor in the experimental process are lost, the condition in a human body cannot be simulated, at present, clinical tumor specimens are very precious, a few special clinical specimens such as puncture specimens and other small specimens can be used for experimental research, the tissue cell quantity is less, the success rate of constructing the nasopharyngeal carcinoma PDX model is low, and the model construction requirement cannot be met.
In summary, in order to explore the mechanism of development of nasopharyngeal carcinoma and develop a novel nasopharyngeal carcinoma therapeutic drug, there is an urgent need for a nasopharyngeal carcinoma animal model that is close to the biological characteristics of nasopharyngeal carcinoma, has short operation time, high repeatability and high flux.
Disclosure of Invention
The invention aims to provide an in-situ primary mouse nasopharyngeal carcinoma model which is closer to the biological characteristics of nasopharyngeal carcinoma, short in preparation period and definite in genotype.
In order to achieve the above object, the present invention provides the following technical solutions:
a culture medium for culturing human or animal nasopharyngeal tissue cell organoids comprises the following formula:
B27 | dilution at 50+ -5-fold concentration |
N-acetylcysteine | 1±0.1mM |
EGF | 50±5ng/mL |
Noggin | 100±10ng/mL |
R-spondin 1 | 250±25ng/mL |
A83-01 | 200±20nM |
FGF10 | 500±50ng/mL |
Nicotinamide | 10±1mM |
Y-27632 | 10±1uM |
WNT3a | 25±2.5ng/mL |
Glutamax | 100+ -10-fold dilution |
N2 | 100+ -10-fold dilution |
Gastrin | 1±0.1nM |
Further, the formula of the culture medium is as follows:
B27 | dilution by 50 times |
N-acetylcysteine | 1mM |
EGF | 50ng/mL |
Noggin | 100ng/mL |
R-spondin 1 | 250ng/mL |
A83-01 | 200nM |
FGF10 | 500ng/mL |
Nicotinamide | 10mM |
Y-27632 | 10uM |
WNT3a | 25ng/mL |
Glutamax | Dilution by 100 times |
N2 | Dilution by 100 times |
Gastrin | 1nM |
A method of constructing an in situ primary nasopharyngeal carcinoma animal model comprising the steps of:
1) Primary culturing of human or animal nasopharyngeal tissue cells;
2) Fixing cells in Matrigel, and adding culture medium to culture into organoids;
3) Resuspending the organoids into single cells, performing genetic engineering, and then culturing the organoids;
4) Injecting the organoids obtained in step 3) into the nasopharynx of the animal;
step 3) the genetic engineering refers to knocking out the oncogene and/or over-expressing the proto-oncogene.
The method as described above, step 2) the medium used to culture the organoids is the medium described above.
The method as described above, step 1) comprising:
a. nasopharyngeal tissue was digested with 0.25% final concentration pancreatin;
b. filtering through 80-130 μm sieve, and collecting cells in the filtrate;
c. neutralizing the filtrate with a cell culture medium, and terminating digestion;
d, 400G, centrifuging for 5min to remove the supernatant, adding a cell culture medium to resuspend cells, and centrifuging to remove the supernatant;
preferably, step b uses a 100 μm sieve.
The cell culture medium in step c and/or d is DMEM/F12 medium as in the previous method.
The method as described above, step 2) comprising:
i. mixing the cells with 30ul Matrigel, and adding a culture medium for culturing after the Matrigel is solidified to obtain organoids;
re-suspending organoids with 1X TrypLE for 15min;
washing the cells with cell culture medium to terminate digestion;
centrifuging to remove the supernatant, adding a cell culture medium to resuspend cells, dispersing the cells, and centrifuging;
adding 30ul Matrigel to re-suspend cells, and adding a culture medium to culture after Matrigel is solidified to obtain organoids.
The method as described above, step 3) further comprising transferring the organoid with a fluorescent marker gene.
The method as described above, the gene editing of step 4) is specifically: overexpressing cMYC genes and Kras G12D mutant genes, and knocking out Cdkn2a genes;
the nasopharyngeal carcinoma is hypodifferentiation squamous carcinoma.
The method as described above, further comprising:
step 5): living imaging observation was performed every 2 to 3 weeks to detect tumor formation.
The method as described above, wherein the animals in steps 1) and 4) are mice.
The method of the invention has the following beneficial effects:
1) Compared with a tumor cell line transplanted tumor model and a human xenograft tumor model, the model constructed by the method does not need to use an immunodeficiency animal, is an in-situ tumor, can simulate the process of converting normal cells into tumor cells in a human body due to genetic change, can dynamically characterize the process of generating and developing tumors, and is closer to the real situation of generating and developing tumors in the aspects of gene level, tumor microenvironment, tumor development, pathophysiology and the like.
2) Compared with a genetic engineering animal model, the tumor model construction method does not need to construct from fertilized eggs or embryos, the period can be obviously shortened, and the problem of early death of animals caused by systemic gene mutation can be avoided.
3) The success rate of the tumor model construction method is high and can reach 75%.
It should be apparent that, in light of the foregoing, various modifications, substitutions and alterations can be made herein without departing from the spirit and scope of the invention as defined by the appended claims.
The above-described aspects of the present invention will be described in further detail below with reference to specific embodiments in the form of examples. It should not be understood that the scope of the above subject matter of the present invention is limited to the following examples only. All techniques implemented based on the above description of the invention are within the scope of the invention.
Drawings
Fig. 1: a schematic flow chart of the in-situ primary nasopharyngeal tumor of the mice is constructed.
Fig. 2: fresh mouse nasopharyngeal tissue was digested with pancreatin into single cells and cultured in Martrilgel for day 1-11 growth conditions.
Fig. 3: the nasopharyngeal organoids of the mice were cultured in vitro.
Fig. 4: HF staining of mouse nasopharyngeal organoids.
Fig. 5: mouse nasopharyngeal organoid gene editing. A. The nasopharyngeal carcinoma model of the invention constructs the schematic diagram; B. schematic diagram of mouse nasopharyngeal organoid gene editing original, edit Cdkn2a gene original: u6 promoter and EFS are promoters, cdkn2a is sgRNA sequence targeting Cdkn2a gene, mCherry is fluorescent protein nucleic acid sequence; overexpression of cMYC gene original: pMSCV and iRES are promoters, cMYC/Kras (G12D) is the gene sequence; C. after lentivirus transfection, nasopharyngeal organoids, mCherry (red fluorescence) detected the efficiency of infection of the Cdkn2a original at organoids; t7 detecting the Cdkn2a gene mutation; E. the cMYC/Kras (G12D) expression original was tested for its efficiency in organoid infection, and higher infection efficiency was considered to be found with a Luciferase number of over 10 ten thousand.
Fig. 6: tumor samples collected after gene editing mice nasopharyngeal organoids were imaged in vivo on day 15, day 30 after in situ transplantation and mice were sacrificed. A, living body imaging; b, performing fluorescence living imaging from the skull; and C, performing fluorescence imaging on tumor tissues.
Fig. 7: in situ primary mouse nasopharyngeal tumor pathology HF staining and Ki67, CK5 and P63 immunohistochemical staining.
Detailed Description
Some of the english abbreviations in the present invention are explained as follows:
DMEM: is a medium with very wide application, can be used for culturing a plurality of mammalian cells and is purchased from GIBCO company.
DMEM/F12: f12 medium and DMEM medium were used according to 1:1, called DMEM/F12 medium. Combines the advantages of the F12 containing rich components and the DMEM containing high-concentration nutrients. Purchased from GIBCO.
Matrigel is separated from EHS mouse tumor rich in extracellular matrix protein, and its main components are laminin, IV type collagen, nidogen, heparan sulfate glycoprotein, etc., and also contains growth factor, matrix metalloproteinase, etc. Purchased from BD company.
B27, a B27 supplement, a commercially available product, can be used to formulate the culture medium. B27 supplement was provided as a 50-fold liquid concentrate comprising, among other ingredients, biotin, cholesterol, linoleic acid, linolenic acid, progesterone, putrescine, retinol acetate, sodium selenite, triiodothyronine (T3), DL-alpha-tocopherol (vitamin E), albumin, insulin, and transferrin. Purchased from Life Technologies company. N-acetylcysteine: n-acetylcysteine, purchased from Sigma company.
EGF, epidermal growth factor, commercially available from R & D company.
Noggin, a cell growth protein component, a commercially available product, purchased from Peprotech company.
R-spondin 1, a human cell growth encoded protein, commercially available from Peprotech.
A83-01, a TGF-beta inhibitor, purchased from Tocris Bioscience.
FGF10, fibroblast growth factor, purchased from Peprotech company.
Nicotinamide, nicotinamide, purchased from Sigma.
Y-27632, ROCK-specific pathway blocker. Purchased from Abmole Bioscience company.
WNT3a, a WNT agonist, a factor in the cell that activates TCF/LEF-mediated transcription, was purchased from PeproTech corporation.
Glutamax, a commercially available cell culture additive, purchased from: GIBCO Co.
N2, N2 supplement was provided as a 100-fold liquid concentrate comprising 500 μg/ml human transferrin, 500 μg/ml
Bovine insulin, 0.63. Mu.g/ml progesterone, 1611. Mu.g/ml putrescine and 0.52. Mu.g/ml sodium selenite. Purchased from Life Technologies company.
Gastin, gastrin, purchased from Sigma company.
TrypLE, a recombinant digestive enzyme for dissociating adherent mammalian cells, purchased from GIBCO corporation.
Kras (G12D), the mutant gene of Kras G12D, i.e. the mutant gene obtained by mutating amino acid 12 of the Kras gene from G to D.
Example 1A method of Forming a mold according to the invention
1. Primary cell culture
Cutting out the nasopharynx tissue of the mouse by using a microscope, and shearing the nasopharynx tissue of the mouse by using a small pair of scissors, wherein the shearing is preferably performed on ice or in the same low-temperature environment; taking sheared tissue blocks, using 5mL pancreatin digestion treatment, incubating for 1h at 37 ℃ by a shaking table, and blowing with a pipetting gun at intervals of about 15-20min for more than ten times to prevent tissue from agglomerating and fully digesting single cells.
Filtering the cells with a 80-130 μm cell screen, preferably a 100 μm cell screen; after filtration, the filter membrane is rinsed by adding 15-20mL of DMEM/F12 and digestion is stopped, and the supernatant is removed by centrifugation; centrifuging to remove supernatant; preferably centrifuging at 2-8deg.C for 4-6min at 400-450 g; the supernatant is removed by adding DMEM/F12 for resuspension, preferably 10mL DMEM/F12 for resuspension, and then centrifuging.
2. Organoid culture
2.1 Pre-culture
Cell count, mix Matrigel,20000 cells per 30 μl, drop in 48 Kong Bankong; transferring to an incubator at 36-38deg.C under 3-8% CO2 for 10-20min, and solidifying Matrigel; 150 μl of cell culture medium, preferably conditioned medium, is added to each well and cultured in a 3-8% CO2 cell incubator at 36-38deg.C; the culture medium is replaced every 4-6 days to culture the nasopharyngeal organoids of the mice. Growth in Martrilgel on days 1-11 after pancreatin digestion of fresh mouse nasopharyngeal tissue into single cells is shown in FIG. 2.
The formula of the conditioned medium is as follows:
note that: 50X means a 50-fold concentration, 100X means a 100-fold concentration, and so on.
2.2 expanded culture
Collecting organoids cultured in a culture dish for about 8-12 days, re-suspending the digested organoids with 1X TrypLE, and digesting for 5-15min at 36-38deg.C; preferably 1ml of TrypLE, the organoids are resuspended and digested at 37℃for 15min. Adding DMEM/F12 to terminate digestion; digestion is preferably terminated by adding 5ml of DMEM/F12.
After the resuspension treatment, the dispersibility of cells in the organoids is recovered, and primitive cells are provided for expansion cultivation.
Centrifuging to remove supernatant, preferably centrifuging at 2-8deg.C for 5min at 400-500 g; preferably 400g, are centrifuged at 4℃for 5min. Matrigel was added to resuspend and dropped into 48 well wells. Preferably, a proper amount of Matrigel reagent is added for the resuspension treatment. Preferably, matrigel is thawed on ice and then added to the previously treated cell fluid. Transfer to a petri dish and solidify Matrigel at 36-39deg.C in the presence of 3-8% CO 2. Preferably, the dish is left in an environment of 37℃C (5% CO 2) for 10min, and the Matrigel is coagulated. Allowing the Matrigel to complete phase inversion at body temperature, forming a gel-like inversion. 150. Mu.L of conditioned medium was added to each well and incubated at 36-39℃in a 3-8% CO2 cell incubator. The composition of the conditioned medium is identical to the composition of the conditioned medium used in the preparation of the nasopharyngeal tissue. The culture medium was changed every 4-6 days to culture nasopharyngeal tissue organoids as shown in FIG. 3.
Organoid H & E staining, as shown in FIG. 4, nasopharyngeal tissue organoids are multicellular in composition, hollow or solid, with good activity profile.
3. Nasopharyngeal cell genetic engineering
The Cdkn2a gene of nasopharyngeal cells was knocked out using CRISPR/Cas9 gene editing technique, and cMYC gene of nasopharyngeal cells, kras G12D mutant gene (abbreviated as "Kras (G12D)") was overexpressed using gene overexpression technique (fig. 5A and B).
3.1 editing operation method is as follows:
(1) Packaging a slow virus (or retrovirus) carrying a genetic modification original (a carrier for CRISPR/Cas9 gene editing, carrying sgRNA and Cas9 protein coding genes and m-Cherry red fluorescent reporter genes), culturing 293T cells in a 6-well plate by using a DMEM culture medium, packaging the virus by using a calcium phosphate precipitation method after the cells grow into the 6-well plate to be low, changing the culture solution every 12 hours, collecting 36 th and 48 th hours virus solutions, filtering the virus solution by using a 022um filter membrane, and preserving the virus solution at 4 ℃ for later use, wherein the virus solution is preferably used within one week.
(2) The cultured mouse nasopharyngeal organoids are digested into single cells, and the single cells are uniformly mixed with the mouse nasopharyngeal cells according to the volume of 500-800ul of each virus liquid, and the single cells are mixed according to the following steps: the volume ratio of the virus liquid is 1:1000 adding ploybrene, transferring the cell virus suspension to a 24-well plate, centrifuging at 2000rpm for 1h, and then placing in a 37 ℃ incubator for 1.5-2h; the cells are resuspended by blowing in a virus liquid, the supernatant is removed by centrifugation, and 400-500g is centrifuged for 5min.
(3) Matrigel was added to resuspend and dropped into 48 well wells. Preferably, a proper amount of Matrigel reagent is added for the resuspension treatment. Preferably, matrigel is thawed on ice and then added to the previously treated cell fluid. Transfer to a Petri dish, place the dish in 37℃ (5% CO 2) environment for 10min, solidify Matrigel. 150. Mu.L of conditioned medium was added to each well and incubated in a 37℃C (5% CO 2) cell incubator. The composition of the conditioned medium is identical to the composition of the conditioned medium used in the preparation of the nasopharyngeal tissue. The culture medium is changed every 4-6 days to culture nasopharyngeal tissue organoids or cell populations.
Viral infection efficiency and gene editing can be identified by fluorescent signal, fluorescent value and T7 cleavage (fig. 5C and D).
3.2 Gene overexpression procedure as follows:
the cMYC gene and the Kras (G12D) gene were inserted into a commercially available overexpression vector at multiple cloning sites to obtain a recombinant overexpression vector carrying the Luciferase gene (fig. 5B). And packaging the recombinant over-expression vector into the lentivirus to obtain the recombinant lentivirus.
And transferring the recombinant lentivirus into nasopharyngeal cells, wherein the steps are the same as those in the steps (2) and (3) in section 3.1.
By detecting the signal value of luciferases, the expression condition of genes in the over-expression vector can be monitored, and the luciferases have a value of more than 10 ten thousand and are considered to have higher infection efficiency (figure 5E).
4. Mouse nasopharyngeal organoids in situ transplantation
Collecting nasopharyngeal cells after gene editing, culturing for 5-7 days to obtain nasopharyngeal organoids, re-suspending organoids with 1ml TrypLE per well, and digesting at 37deg.C for 5min; digestion is terminated by adding DMEM/F12, preferably by adding 5ml DMEM/F12; centrifuging at 400g for 5min, and removing supernatant; cells were resuspended using 10-15ul Matrigel and placed on ice.
Isoflurane is used for anesthetizing the Nude mice in an anesthesia machine, the anesthetized mice lie on the back, and the four limbs of the mice are fixed by using an adhesive tape; sucking Matrigel cell suspension with insulin needle, opening the mouth of the mouse by using surgical forceps, and transplanting the cell suspension to the nasopharynx of the mouse; the mice were returned to the SPF animal house for feeding, periodically replaced with sterile water and feed, and the condition of the mice was examined, and imaged in vivo every 2 weeks. When the state of the mice starts to worsen, the mice are sacrificed by cervical fracture, and tumor samples are collected.
FIG. 6A shows in vivo imaging at day 15 and day 30 post-implantation, showing that the area occupied by transplanted gene-editing cells is significantly larger. FIGS. 6B and 6C show the detection of mCherry and GFP fluorescence signals at the cranium and nasopharynx sites, respectively, of mice after sacrifice, where mCherry and GFP fluorescence signals were detectable, infected DNA elements carrying mCherry, trp53-/-Cas9 gene mice endogenously expressing GFP protein, and mCherry and GFP positive signal tissues from exogenously transplanted cells.
Pathological HE staining and immunohistochemical staining are carried out on nasopharyngeal tumors, as shown in fig. 7, and the result shows that the nasopharyngeal of the mouse transplanted with the gene editing organoids forms a bump space, the cell nucleus is deeply stained, the heterogeneity is large, the nuclear mass ratio is large, and part of cell nuclei are exposed; the Ki67 positive tumor tissue and the classical squamous Marker CK5 and P63 positive tumor tissues are hypodifferentiation squamous cancers, and are consistent with the clinical nasopharyngeal carcinoma which is mainly hypodifferentiation squamous cancers.
In the embodiment, the modeling is performed on 4 mice in total, wherein 3 mice detect solid tumors, the modeling success rate is 75%, and the success rate is high.
In summary, the method can efficiently prepare the nasopharyngeal carcinoma model which is more similar to the characteristics of the nasopharyngeal carcinoma and meets the clinical research requirements; the model can provide a favorable tool in the research fields of exploring the occurrence and development mechanism of the nasopharyngeal carcinoma, searching and optimizing a new possible treatment mode of the nasopharyngeal carcinoma and the like.
Claims (8)
1. A method for constructing an in situ primary nasopharyngeal carcinoma animal model, comprising the steps of:
1) Primary culture of mouse nasopharyngeal tissue cells;
2) Fixing cells in Matrigel, and adding culture medium to culture into organoids;
3) Resuspending the organoids into single cells, performing genetic engineering, and then culturing the organoids;
4) Injecting the organoid obtained in the step 3) into the nasopharynx of the mouse;
step 3) refers to knocking out the oncogene and/or over-expressing the proto-oncogene, specifically: overexpressing cMYC genes and Kras G12D mutant genes, and knocking out Cdkn2a genes; the nasopharyngeal carcinoma is hypodifferentiation squamous carcinoma.
2. The method of claim 1, wherein:
step 2) the formulation of the medium used to culture organoids is as follows:
。
3. The method of claim 2, wherein: the formula of the culture medium is as follows:
4. a method according to any one of claims 1-3, wherein:
step 1) comprises:
a. nasopharyngeal tissue was digested with 0.25% final concentration pancreatin;
b. filtering through 80-130 μm sieve, and collecting cells in the filtrate;
c. neutralizing the filtrate with a cell culture medium, and terminating digestion;
d 400G, centrifuging for 5min to remove the supernatant, adding cell culture medium to re-suspend the cells, and centrifuging to remove the supernatant.
5. The method of claim 4, wherein: step b uses a 100 μm sieve.
6. A method according to any one of claims 1-3, wherein:
step 2) comprises:
i. mixing the cells with 30ul Matrigel, and adding a culture medium for culturing after the Matrigel is solidified to obtain organoids;
re-suspending organoids with 1X TrypLE for 15min;
washing the cells with cell culture medium to terminate digestion;
centrifuging to remove the supernatant, adding a cell culture medium to resuspend cells, dispersing the cells, and centrifuging;
adding 30ul Matrigel to re-suspend cells, and adding a culture medium to culture after Matrigel is solidified to obtain organoids.
7. A method according to any one of claims 1-3, wherein:
the step 3) also comprises the step of transferring the organoid into a fluorescence marker gene.
8. A method according to any one of claims 1-3, wherein:
it also includes:
step 5): living imaging observation was performed every 2 to 3 weeks to detect tumor formation.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011107955.9A CN114369573B (en) | 2020-10-15 | 2020-10-15 | Method for constructing in-situ primary nasopharyngeal carcinoma animal model |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011107955.9A CN114369573B (en) | 2020-10-15 | 2020-10-15 | Method for constructing in-situ primary nasopharyngeal carcinoma animal model |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114369573A CN114369573A (en) | 2022-04-19 |
CN114369573B true CN114369573B (en) | 2023-09-08 |
Family
ID=81138106
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011107955.9A Active CN114369573B (en) | 2020-10-15 | 2020-10-15 | Method for constructing in-situ primary nasopharyngeal carcinoma animal model |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114369573B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117821386A (en) * | 2022-09-28 | 2024-04-05 | 合肥中科普瑞昇生物医药科技有限公司 | Culture medium for nasopharyngeal carcinoma organoid culture, and culture method and application thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016015158A1 (en) * | 2014-07-30 | 2016-02-04 | University Health Network | Organoids for drug screening and personalized medicine |
CN106967672A (en) * | 2017-03-24 | 2017-07-21 | 四川大学华西医院 | Lung and lung cancer tissue culture method and method for constructing lung cancer mouse animal model by using same |
CN109679915A (en) * | 2019-02-27 | 2019-04-26 | 南方医科大学南方医院 | A kind of culture of nasopharyngeal carcinoma organoid and identification method |
CN110066767A (en) * | 2019-05-27 | 2019-07-30 | 创芯国际生物科技(广州)有限公司 | A kind of tissues of nasopharyngeal carcinoma organoid culture medium and cultural method |
WO2019226120A1 (en) * | 2018-05-23 | 2019-11-28 | Agency For Science, Technology And Research | A tumour cell culture system and a method of preparing a tumour cell culture system |
-
2020
- 2020-10-15 CN CN202011107955.9A patent/CN114369573B/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016015158A1 (en) * | 2014-07-30 | 2016-02-04 | University Health Network | Organoids for drug screening and personalized medicine |
CN106967672A (en) * | 2017-03-24 | 2017-07-21 | 四川大学华西医院 | Lung and lung cancer tissue culture method and method for constructing lung cancer mouse animal model by using same |
WO2019226120A1 (en) * | 2018-05-23 | 2019-11-28 | Agency For Science, Technology And Research | A tumour cell culture system and a method of preparing a tumour cell culture system |
CN109679915A (en) * | 2019-02-27 | 2019-04-26 | 南方医科大学南方医院 | A kind of culture of nasopharyngeal carcinoma organoid and identification method |
CN110066767A (en) * | 2019-05-27 | 2019-07-30 | 创芯国际生物科技(广州)有限公司 | A kind of tissues of nasopharyngeal carcinoma organoid culture medium and cultural method |
Non-Patent Citations (1)
Title |
---|
Human gastric cancer modelling using organoids;Seidlitz, T等;GUT;第68卷(第2期);摘要,第7页左栏第2段-右栏最后1段 * |
Also Published As
Publication number | Publication date |
---|---|
CN114369573A (en) | 2022-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106967672B (en) | Lung and lung cancer tissue culture method and method for constructing lung cancer mouse animal model by using same | |
Zhang et al. | CRISPR/Cas9‐mediated sheep MSTN gene knockout and promote sSMSCs differentiation | |
CN111876386B (en) | Breast cancer organoid culture method and co-culture method of tumor-related fibroblasts | |
CN104350145B (en) | The method of stem spermatogonium for no feeder cells culture ox and pig | |
CN103146644B (en) | Technical method for differentiating mouse hair follicle stem cells to primordial germ cells in vitro | |
US20070238175A1 (en) | Standardization of processes for culturing primary cells | |
CN113151149B (en) | Method for inducing lung organoids and establishment of experimental model | |
CN112852714B (en) | Method for constructing in-situ primary lung cancer animal model | |
CN114075538B (en) | Method for constructing in-situ primary endometrial cancer animal model | |
CN114075539B (en) | Method for constructing in-situ primary bladder cancer animal model | |
CN114369573B (en) | Method for constructing in-situ primary nasopharyngeal carcinoma animal model | |
JP2003516141A (en) | Long-term cell culture compositions and genetically modified animals derived therefrom | |
CN113943755B (en) | Method for constructing in-situ primary esophageal cancer animal model | |
CN112852709B (en) | Method for culturing mouse lung organoid | |
CN118345040A (en) | Novel culture medium for culturing colorectal cancer organoids | |
CN114480250B (en) | Method for constructing in-situ primary gastric cancer animal model | |
AU2014202292B2 (en) | Stem cell preparations and methods of use | |
CN111876383B (en) | Quasi-organ lung cancer PDXO model, EGFR (epidermal growth factor receptor) engineering modification and application of PDXO model in tumor drug pharmacodynamic research | |
CN115466716A (en) | Construction method and application of patient-derived oral mucus epidermoid carcinoma organoid | |
Rubio et al. | Generation of mosaic mammary organoids by differential trypsinization | |
CN117050934B (en) | Preparation method of mouse prostate organoid and primary in situ prostate cancer animal model | |
CN114438032B (en) | Composition, culture medium and method for 3D culture of laryngeal cancer tissues | |
CN117448276A (en) | Preparation method of cervical cancer vascularized organoid | |
CN117987373A (en) | Method for constructing gastric seal ring cell cancer animal model | |
CN118064350A (en) | Kit for constructing endometrium organoid and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |